CD274 and urinary bladder carcinoma: As anti-PD1/PL-1 antibodies are being adopted as standard therapy for patients with locally advanced and metastatic bladder cancer, and as PD-L1 expression is associated with response to these therapies, the work presented here has immediate translational implications for the identification of bladder cancer patients most likely to respond to immune checkpoint blockade.